% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • fezziwig2008 fezziwig2008 Apr 29, 2014 8:55 AM Flag

    One Case Against PH20- Interferes w Remyelination via Oligodendrocyte (OPC) Maturation Inhibition- Prevents Stroke Repair

    Zheng Gang Zhang,1 Michael Chopp1,2
    1. Department of Neurology, Henry Ford Hospital, Detroit, Michigan, USA
    2. Department of Physics, Oakland University, Rochester, Michigan, USA
    Disclosure: This work was supported by National Institutes of Health Grants RO1 NS075156 (ZGZ) and
    AG037506 (MC). The content is solely the responsibility of the authors and does not necessarily represent
    the official view of the National Institutes of Health.
    Received: 07.10.13 Accepted: 25.10.13
    Citation: EMJ Neurol. 2013;1:26-31

    New oligodendrocytes derived from non-myelinating
    oligodendrocyte progenitor cells (OPCs) are required
    to form myelin sheaths for sprouting axons during
    brain repair processes after brain injury.

    Inhibition of PH20 Hyaluronidase May Effectively Promote Remyelination in Multiple Sclerosis Lesions

    Posted January 9, 2014
    Larry Sherman, Ph.D., Oregon Health & Science University, and Paul Weigel, Ph.D., Oklahoma Health Sciences Center

    Interestingly, HA digestion products formed by PH20, but not the others, inhibited OPC maturation and thus prevented remyelination.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • More implications for Coformulated and Insulin Pump Hylenex

    • PH20 is not the only anti-tumpr Hyaluronidase- HYAL1 and HYAL2 are as well in vivo.
      HYAL1 and HYAL2 Inhibit Tumour Growth In Vivo but Not In Vitro

      Jingfeng Li equal contributor,

      Vera N. Senchenko,

      •DOI: 10.1371/journal.pone.0003031

      The results suggest that the expression of either gene has led to inhibition of tumour growth in vivo without noticeable effect on growth in vitro. HYAL1 and HYAL2 thus differ in this aspect from other tumour suppressors like P53 or RASSF1A that inhibit growth both in vitro and in vivo. Targeting the microenvironment of cancer cells is one of the most promising venues of cancer therapeutics. As major hyaluronidases in human cells, HYAL1 and HYAL2 may control intercellular interactions and microenvironment of tumour cells providing excellent targets for cancer treatment.

    • So I guess stroke should be avoided in the first place - novel concept, eh? Again - the $2 blood thinner makes $HALO a winner! Next.

      Sentiment: Buy

9.40-0.20(-2.08%)Oct 21 4:00 PMEDT